MedTrace Logo

Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging

NCT02462213 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2017-10-26

No results posted yet for this study

Summary

Cardiac amyloidosis describes a process by which abnormally folded proteins infiltrate the heart tissue. Given the insidious nature of this disease process, diagnosis is often too late for a meaningful intervention. Advances in the treatment of the amyloidoses have improved outcomes for patients with these conditions. The focus of this study is to identify the involvement of the heart, most closely associated with mortality, so that aggressive management can be instituted improving prognosis.

Conditions

  • Amyloidosis
  • Paraproteinemias
  • Cardiomyopathies

Interventions

OTHER

Amyloidosis

Patients with amyloidosis without cardiac involvement will undergo cardiac MRI and possible biochemical analysis during the course of the study.

OTHER

Cardiac Amyloidosis

Patients with confirmed cardiac amyloidosis will undergo cardiac MRI and possible biochemical analysis during the course of the study.

Sponsors & Collaborators

  • The Christ Hospital

    collaborator OTHER

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Robert E O'Donnell, MD MSc · University of Cincinnati

  • Jennifer Daniels, MSc · University of Cincinnati

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462213 on ClinicalTrials.gov